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Activation of the HIV-1 promoter by the virally encoded Tat protein is characterized by efficient processive transcription,
mediated by host cell factors that are tethered to the promoter with the Tat–TAR RNA complex. Importantly, viral gene
activation has been shown to be stimulated in mitogenically induced cells, although the link between cell cycle regulation and
viral gene activation is unclear. We reported a Tat-associated CAK/CTD kinase from mitogenically induced primary human
T-cells (TTK) (S. Nekhai et al., 1997, J. Virol. 71, 7436–7441). Here, biological activity of the kinase has been studied by direct
microinjection at the individual-cell level. The TTK-dependent Tat response is maximal during G1 phase as shown by
co-injection with Tat protein in cells synchronized at the various stages of the cell cycle. The cell cycle dependence of the
Tat response was confirmed by inhibiting G03 G1 progression with the expression of dominant negative mutant RasAsn17 or
the cyclin-dependent kinase CDK4. The results support a mechanism whereby transactivation of the HIV promoter is
regulated by cell growth signal transduction pathways that target the Tat cofactor. © 2000 Academic Press
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Mitogenic stimulation of the host cells in a number of
studies has been shown to be related to viral activation
and induction of viral gene expression (Adams et al.,
1994; Ascher et al., 1995; Bukrinsky et al., 1991; Fauci,
996). In the case of human immunodeficiency virus type
(HIV-1), since the regulation of gene expression is
ependent upon virally encoded Tat protein, we rea-
oned that the Tat response in particular may be cell
ycle regulated. Tat-mediated transactivation of the
IV-1 LTR principally stimulates efficient elongation of
iral transcripts (Gaynor, 1995; Jones and Peterlin, 1994;
een et al., 1996; Laspia et al., 1989; Marciniak and
harp, 1991). It has been suggested that efficient proces-
ive transcription of the HIV-1 promoter in response to
at protein involves the cooperative interaction between
he RNA polymerase II (RNA Pol II) complex and specific
ranscriptional coactivators (Zack et al., 1990; Yankulov et
l., 1994; Mavankal et al., 1996; Parada and Roeder, 1996;
ei et al., 1998; Yang et al., 1996; Zhou et al., 1998). A
ossible mechanism would include specific interaction
f cellular factors with Tat protein which likely modify the
ranscription complex, rendering it more efficient in tran-
cript elongation. Here we examine the properties of
uman primary T-cell derived Tat-associated RNA Pol II
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24-terminal domain (CTD) kinase (TTK), in particular its
egulation of the Tat response during the cell cycle.
One of the essential mechanisms by which promoter
learance and transcriptional elongation are stimulated
s by enhanced phosphorylation of the largest subunit of
he RNA Pol II CTD (Cadena and Dahmus, 1987; O’Brien
t al., 1994). Thus the hypophosphorylated form associ-
tes with the preinitiation complex and is subsequently
yperphosphorylated by the general transcription factor
FIIH-associated kinase (Lu et al., 1991, 1992; Shiekhat-
ar et al., 1995; Zhou et al., 1998). The TFIIH-associated
inase is a trimeric complex of cyclin-dependent kinase
CDK) 7, cyclin H, and MAT1/p36 (designated CAK, CDK-
ctivating kinase), which plays an essential role in pos-
tive regulation of CDKs during the cell cycle (Feaver et
l., 1994; Fisher and Morgan, 1994; Roy et al., 1994;
assan et al., 1995; Shiekhattar et al., 1995; Fisher et al.,
995). It is unclear how the cellular CAK activity is in-
uced and whether the CAK can be specifically stimu-
ated by transcriptional activators, such as HIV-1 Tat.
One likely target of the Tat-mediated transcriptional
longation mechanism is the phosphorylated state of the
TD repeats of RNA Pol II (Herrmann and Rice, 1995;
errmann et al., 1996; Parada and Roeder, 1996; Garcia-
artinez et al., 1997). Promoter-specific transcriptional
ctivators, such as Tat, have been shown to induce CAK
ctivity (Cujec et al., 1997; Garcia-Martinez et al., 1997;
Nekhai et al., 1997; Parada and Roeder, 1996; Zhou and
Sharp, 1995). A 42-kDa Tat-associated kinase, TAK (Herr-
mann and Rice, 1995), which is related to the Drosophila
multicomponent positive transcription elongation factor b
(P-TEFb) and its human homologue CDK9 (Zhu et al.,
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247STIMULATION OF HIV-1 BY TAT-ASSOCIATED CAK ACTIVATOR1997), has recently been shown (Garber et al., 1998; Wei
et al., 1998) to form an active complex with Tat. The
Tat–CDK9 complex formation is mediated by cyclin T
cofactor which specifically recognizes the active domain
of Tat and the TAR RNA loop sequence (reviewed in
Cullen, 1998). The mechanism of regulation of transcrip-
tional elongation by the multicomponent CDK9 cofactors,
however, appears to be complex (Zhu et al., 1997; Garber
et al., 1998; Peng et al., 1998; Zhou et al., 1998). The issue
is what other Tat cofactors are required for Tat response
in vivo.
We have argued that as a part of the Tat-mediated
transactivation of the HIV-1 promoter, Tat protein will
tether essential CTD kinase such as TTK in order to
maintain RNA polymerase II in the hyperphosphorylated
state, with its ability to induce CAK activity, and thus
sustain efficient, processive transcription (Nekhai et al.,
1997). We further fractionated the TTK and identified its
components by amino acid sequencing (S. Nekhai et al.,
1999, unpublished). The TTK complex contained two sub-
fractions, one containing the CAK components (CDK7
and cyclin H) and a second which includes a PISTAIRE-
like kinase whose ability to activate CAK is dependent
upon CDK7 phosphorylation, indicating a positive regu-
lation of CAK by the Tat-associated kinase (S. Nekhai et
al., 1999, unpublished). In the present paper, TTK frac-
tionated from primary T-cells was examined for its ability
to support HIV long terminal repeat (LTR) expression at
different stages of cell cycle.
It is likely that cell cycle regulation of viral gene acti-
vation is mediated by regulating the function of Tat co-
factors such as TTK. In this report, we discuss specific
induction of HIV-1 LTR in vivo by the TTK, using direct
microinjection of Tat-responsive LTR-LacZ reporter con-
structs into human primary fibroblasts. The ability to
assay the expression of reporter genes within a narrow
window of 2–3 h after their introduction into synchronized
cells allowed us to study the effects of cell cycle pro-
gression on viral gene expression. Results show that
TTK-mediated induction of the HIV-1 promoter is aug-
mented in cells entering the mitotic cycle, and the re-
sponse is blocked by inhibitors of cell cycle progression,
particularly those that delay G0 3 G1 transition. The
results suggest a mechanism whereby the regulation of
HIV-1 gene transactivation is coupled to the signal trans-
duction pathways controlling G1 progression, in particu-
lar CDK4 activity.
RESULTS
A number of studies utilizing either cell-free systems
or DNA-mediated transfection assays have defined the
promoter elements and the Tat response domains es-
sential for transactivation of the HIV-1 LTR (Gaynor, 1995;
Jones and Peterlin, 1994). The mechanism of regulation
of viral gene activation during the cell cycle and the role iof cell growth signal transduction pathways that are
involved in viral induction, however, remain unclear. We
utilized direct microinjection of HIV-1 LTR-driven reporter
constructs into human primary cells (which were syn-
chronized for the G0 to G1 phase of the cell cycle) to
study the induction of the HIV-1 promoter by Tat and Tat
cofactors during the cell cycle. The ability to assay the
expression of the indicator, b-galactosidase, by immuno-
staining within 3 h after nuclear injection enabled us to
study the effect of specific cell cycle regulatory pathways
on the viral promoter. Importantly, this assay system
allows evaluation of the effects of purified Tat cofactors
on LTR transactivation in individual cells.
To assess whether the Tat-associated kinase specifi-
cally induced transactivation of the HIV-1 LTR, and if
such activation of the viral promoter is cell cycle regu-
lated, we isolated a candidate Tat-associated kinase
(TTK) from mitogenically induced human primary T-cells
which contained CAK as well as CAK-activation proper-
ties (Nekhai et al., 1997). Further resolution of the TTK
rom Jurkat T-cells (S. Nekhai et al., 1999) showed two
inase complexes, TTK1a and TTK1b. The TTK1a in-
luded the CAK components, CDK7 and cyclin H, but
acked the ability to induce CAK. The TTK1b contained a
ISTAIRE-like kinase and four other proteins (35, 60, 83,
nd 150 kDa) with sequence homology to yet unnamed
uman genes. Furthermore, TTK1b induced CAK by
hosphorylating CDK7 (Fig. 1B). However, neither TTK
omponent contained CDK9 in immunoblot assays (S.
ekhai et al., 1999). In the present report, which is fo-
used on its biological activity, the TTK was fractionated
y conventional chromatography (Fig. 1A) and its com-
osition is similar to TTK1b, which will be described
lsewhere (S. Nekhai et al., 1999).
To ascertain the functional significance of the TTK and
ts similarity to the TTK1b, we demonstrate that TTK
unctions by phosphorylating CDK7 and thus promoting
ssociation of CDK7 with cyclin H and formation of active
AK (Fig. 1B). In the absence of CDK7 phosphorylation,
here is no coimmunoprecipitation of cyclin H with anti-
DK7 antibody (Fig. 1B, lane 1). However, when CDK7 is
reincubated with cdc2/cyclin B (MPF), which is known
o phosphorylate CDK7, there is a coimmunoprecipitation
f cyclin H with CDK7 (Fig. 1B, lane 2). Addition of TTK
raction, however, resulted in coprecipitation of cyclin H
ith CDK7 antibody at a level similar to that seen when
PF was used as CDK7 kinase (Fig. 1B, lane 3), sug-
esting that the TTK fraction contains kinase activity to
hosphorylate the T loop of CDK7 (since the CDK7 mu-
ants lacking the phosphorylation site were not activated
y TTK; not shown). Therefore, TTK purified from human
rimary T-cells includes CAK-inducing activity as we
uggested before (Nekhai et al., 1997; and unpublished
bservations).In the present report we have focused on the biolog-
cal activity of the primary T-cell-derived Tat-associated
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248 NEKHAI ET AL.kinase by direct microinjection into human cells and
examined its regulation by cell cycle-dependent kinases.
TTK functions as an inducer of Tat response
To examine the activation of viral promoter in response
to Tat and the Tat-associated kinase (TTK), we microin-
jected HIV-LTR-LacZ reporter plasmid or the reporter
constructs containing mutations of the Tat target (TAR)
sequence along with Tat and TTK. As is shown in Fig. 2,
induction of the viral promoter is entirely dependent upon
the inclusion of Tat protein. When Tat protein and the
reporter plasmid were injected together, there was a
marked induction of b-galactosidase expression within
h (Fig. 2, compare 2A and 2B). Inclusion of TTK spe-
ifically augmented Tat-mediated transactivation of viral
romoter (Figs. 2A–2C), whereas no LacZ expression
as induced by TTK in the absence of Tat protein (data
FIG. 1. (A) The fractionation of TTK is outlined as described under
Materials and Methods. A portion of each fraction was assayed for
Tat-associated CTD kinase activity. Fractions enriched in the kinase
activity were subjected for further purification. (B) TTK stimulated co-
immunoprecipitation of cyclin H with CDK7. A mixture of in vitro-
translated and transcribed CDK7 and cyclin H was supplemented with
cdc2/cyclin B (MPF) or Tat-associated kinase fraction (TTK) and immu-
noprecipitated with anti-CDK7 antibody. The reactions were resolved
on 12% SDS–PAGE and analyzed by fluorography. The positions of
[35S]methionine-labeled CDK7 and cyclin H are indicated.ot shown), indicating that the TTK does not introduce a
onspecific activation. This effect of Tat-associated ki-ase is specific for HIV-LTR expression since there was
o effect of Tat or TTK plus Tat on the b-actin promoter
Figs. 2D–2F). Further evidence that the induction of the
IV-1 promoter by TTK is dependent upon Tat-mediated
ransactivation comes from the observation that little or
o response to added Tat plus TTK is seen if the reporter
onstructs contained mutations of the TAR region (Boris-
awrie et al., 1992; Rounseville and Kumar, 1992) that
endered the promoter nonresponsive to Tat. The LTR
utants used included deletions of the TAR domain
LM5, deleted residues 120–57; LM7, deleted residues
1–20) or base substitutions (LM11 contained substitu-
ions of the pyrimidine bulge domain required for Tat
inding). Figure 3 shows a summary of the results of
arious HIV-1 LTR–TAR mutants (the effects of the TAR
utations on Tat response were independently con-
irmed by DNA-mediated transfection assays, not
hown). Together, these results indicate that the Tat-
ssociated kinase fractions induce HIV-1 LTR only in the
ontext of normal Tat-mediated transactivation, a conclu-
ion supported by the observation that the expression of
he b-actin promoter, which is not affected by Tat, re-
mains unchanged in the presence of TTK (Fig. 2D—actin
promoter does require serum factors, there was no b-ac-
in-LacZ expression in quiescent cells, not shown).
TK stimulates transactivation in mitogenically
nduced cells
Induction of viral gene expression when quiescent
ells are stimulated to enter the cell division cycle has
een noted in a variety of studies (Bukrinsky et al., 1991;
auci, 1996; Zack et al., 1990). We reasoned therefore
hat a Tat cofactor, such as the TTK, might regulate
at-mediated transactivation of the viral promoter at spe-
ific stages of the cell cycle. Human primary fibroblasts,
S68 cells, arrested at G0 phase showed minimal Tat
ransactivation of LTR-LacZ reporter plasmids compared
o during the later stages in the cell cycle. As is shown in
ig. 4, inclusion of Tat-associated kinase augmented Tat
esponse, most markedly during the G0 to G1 transition.
We considered the possibility that the co-injected re-
ombinant Tat protein may not efficiently associate with
ell cycle-specific Tat cofactors as would be expected of
at expressed in vivo. We therefore expressed HIV-1 Tat
nder the control of a tetracycline-inducible promoter.
nitial tests showed that 30 min treatment with 2 mM
etracycline was sufficient to induce functional Tat pro-
ein (as assayed by the stimulation of LTR-LacZ). As
xperimental controls, we observed that stimulation of
he HIV-1 LTR was strictly dependent on the induction of
unctional Tat, since there was no b-galactosidase ex-
pression when cells injected with pTet-Tat and HIV-1
LTR-LacZ (pJK2) were not treated with tetracycline or
when cells injected with pJK2 without pTet-Tat were
treated with tetracycline (not shown). As is shown in Fig.
4
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249STIMULATION OF HIV-1 BY TAT-ASSOCIATED CAK ACTIVATOR5, Tat protein expressed at different stages of the cell
cycle induced HIV-1 LTR transactivation (which was aug-
mented upon inclusion of TTK) to levels similar to those
seen with co-injected recombinant Tat protein (compare
Fig. 5 to Fig. 4). Interestingly enough, Tat induced in vivo
also stimulates transactivation in G2 phase, suggesting
cell cycle-specific Tat cofactors, although their exact
FIG. 2. Expression of HIV-1 LTR or b-actin promoter-driven b-galactos
8 h incubation in growth medium lacking serum prior to microinjection
lus Tat protein (B, B1, and B2), or pJK2 plasmid plus Tat protein and Ta
acZ was under control of the b-actin promoter was injected alone in D
lasmids was adjusted to 8–10 molecules each per nuclei and rabbit Ig
ells as described under Materials and Methods. Microinjected cells w
ixed, and examined for immunofluorescence in early G1m within 3 h
with FITC-conjugated antibodies. (A1, B1, and C1) Staining for injectionidentity remains unclear. Thus the Tat-associated kinase
augments Tat response equally efficiently, whether theHIV-1 LTR is induced with the recombinant Tat protein or
whether Tat is expressed in vivo.
Induction of transactivation requires CTD repeats
Biochemical properties of Tat-associated kinase indi-
cated that Tat-mediated transactivation required the RNA
in human fibroblasts. HS68 human fibroblasts rendered quiescent with
TR-LacZ expression plasmid (pJK2) alone (A, A1, and A2), pJK2 plasmid
ciated CTD kinase (TTK) (C, C1, and C2). The control plasmid in which
at protein in E, and with Tat and TTK in F. The amount of proteins and
included in all microinjections for subsequent identification of injected
lowed to enter the cell cycle upon serum stimulation in fresh medium,
icroinjection. (A–F) Staining for b-galactosidase expression visualized
r, rabbit IgG, and (A2, B2, and C2) DNA staining (with Hoechst).idase
with L
t-asso
, with T
G was
ere alPol II CTD repeats (Yang et al., 1996; Nekhai et al., 1997).
It was important, therefore, to confirm the CTD require-
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250 NEKHAI ET AL.ment of TTK-induced Tat response at the individual cell
level in vivo. We assessed CTD requirement of the Tat
response by introducing plasmids expressing a-aman-
itin-resistant large subunit of RNA Pol II containing dif-
ferent-length CTD repeats (Gerber et al., 1995). Results
summarized in Fig. 6 confirm and extend the previous
reports, that the Tat transactivation of the HIV-1 LTR is
FIG. 3. Tat-associated kinase is ineffective with LTR–TAR mutants
that are deficient in Tat-mediated transactivation. HS68 cells were
synchronized in G1 phase and injected with either wild-type LTR–LacZ
(pJK2) or LTR–TAR mutant constructs, with or without Tat or Tat plus
Tat-associated kinase, TTK. A total of 48 cells were injected with pJK2.
The LTR–TAR mutant, LM5, had nucleotides 120 to 157 deleted, LM7
had a deletion of nucleotides 11 to 119, and LM11 had substitutions
f the wild-type nucleotides UCU (139 to 141) with AGA. Total number
f cells injected for each LTR–TAR mutant varied from 35 to 52 for each
icroinjection. The results represent an average of injected nuclei that
re b-Gal positive, from two or more independent assays.
FIG. 4. Regulation of the Tat response in cell cycle: quantitation of
immunostained b-galactosidase expression. Cells were injected at the
indicated phases of the cell cycle and assayed 3 h postinjection follow
immunostaining as described under Materials and Methods. Total
number of cells injected varied from 30 to 55 for each condition. TheD
i
results are the averages of the b-Gal-positive nuclei, based on two
ndependent assays.dependent upon the CTD repeats (Chun and Jeang, 1996;
Okamoto et al., 1996). As is shown in Figs. 6A and 6B, the
a-AMr Pol II large subunit containing (wild-type) 52 CTD
repeats or only 31 repeats restored Tat response ap-
proaching the level in untreated cells (Fig. 6A, pHAwt and
pHA31). Down to 5 CTD repeats is clearly insufficient to
promote Tat transactivation (Fig. 6, pHA5).
Furthermore, in agreement with the results presented
above, the Tat response is most effective in cells pro-
gressing from G0 to G1 phase (Fig. 6B). Curiously
enough, the CTD dependence of Tat transactivation at
G2 appears to be more stringent (Fig. 6B), since 31 CTD
repeats are less efficient in G2 than in G1. The differ-
ences in transactivation in the presence of a-AMr Pol II
are unlikely to be due to the differences in the level of
expression of a-AMr protein (immunostaining of HA-
tagged a-AMr protein showed similar levels in all cases,
ot shown).
nhibition of G1 progression blocks Tat function
To address the possibility that the cell cycle regulation
f Tat response we observed may be an artifact of cells
ynchronized by serum starvation, we examined the ef-
ects of CDKs required for G03 G1 progression with the
xpression of dominant negative mutants. The Ras proto-
ncogene function has been shown to be required for
xit from quiescent, G0 phase (Mulcahy et al., 1985;
FIG. 5. Tat-associated kinase augments Tat transactivation: probed
by inducible Tat expression at specific stages of the cell cycle. The
pJK2 plasmid was injected, together with the tetracycline-inducible Tat
expression vectors (described under Materials and Methods), into cells
synchronized at different phases of their cycle. Tat expression was
induced by 50 min incubation with tetracycline (2 mg/ml), before fixation
nd staining as for Fig. 2. Total number of injected cells ranged from 30
o 40 per assay.obrowolski et al., 1994). We studied the effect of Ras
nhibition by coexpression of the Ras-dominant negative
251STIMULATION OF HIV-1 BY TAT-ASSOCIATED CAK ACTIVATORmutant, RasAsn17 (Cai et al., 1990; Peeper et al., 1997).
Consistent with the requirement of Ras protein in G0 to
G1 transition, coexpression of RasAsn17 in quiescent cells
at G0 that were serum induced to enter G1 phase
showed marked inhibition of Tat response (Fig. 7A, fluo-
rescence staining of microinjected cells; results of a
large number of injected nuclei are summarized in Fig.
7B).
In addition, since the transit from resting to growing
state is mediated by cyclin-dependent kinase activity, we
examined whether the dependence of Tat response on
G1 progression was sensitive to cell cycle regulatory
CDK activity (Pardee, 1989; Sherr, 1993; Xiong et al.,
1993). Coexpression of the CDK inhibitor p27 blocked
Tat-mediated transactivation of the HIV-1 LTR (Fig. 7).
Since p27 blocks CDK activity by binding to the CDK–
cyclin complex and it is a rather general inhibitor of all
the CDKs, we next examined the effect of p16, a G1-
specific CDK inhibitor. The p16 family of CDK inhibitors
blocks G1 progression by binding specifically to CDK4
and CDK6, thus preventing cyclin binding and subse-
quent CDK activity (Serrano et al., 1995; Sherr and Rob-
erts, 1995). As illustrated in Fig. 7A, left, coexpression of
p16 blocked Tat response equally efficiently, suggesting
that Tat response is dependent on G1 progression.
To confirm the requirement of G1-specific CDK func-
tion on Tat-mediated transactivation of the HIV-1 LTR, we
studied the effects of coexpression of dominant negative
mutant CDKs on Tat response. As shown in Fig. 7A, right,
inhibition of CDK4 by coexpression of the CDK4 domi-
nant negative mutant (Kato and Sherr, 1993) showed the
most marked effect in blocking Tat response, consistent
with the results of p16 inhibition. There was only a
modest effect of coexpression of CDK2 and CDK3 dom-
inant negative mutants on Tat response (Fig. 7A, right).
Thus the results suggest that the cell cycle progression
through G1 phase, and in particular the activity of the
G1-specific CDK4, is required for HIV-1 Tat transactiva-
tion.
DISCUSSION
The principal effect of Tat in stimulating HIV-1 gene
expression has been observed as efficient promoter
clearance and transcriptional elongation (reviewed in
Cullen, 1998; Gaynor, 1995; Jones and Peterlin, 1994). Tat
could mediate its effect on enhanced processivity of RNA
polymerase II by a number of mechanisms, each envi-
sioned as a specific interaction of Tat with host cell
factors, either to increase RNA polymerase II elongation
properties (Zawel and Reinberg, 1995; Zhou and Sharp,
1995) or to increase RNA Pol II CTD phosphorylation by
direct interaction with a cellular kinase (Herrmann and
Rice, 1995; Herrmann et al., 1996; Garcia-Martinez et al.,
1997; Nekhai et al., 1997; Zhu et al., 1997). It is likely,
however that the induction of the HIV-1 LTR may utilizeother kinases, in addition to Tat-associated CDK9/cyclin
T (Parada and Roeder, 1996; Keen et al., 1996; Cujec et
al., 1997; Garcia-Martinez et al., 1997; Nekhai et al., 1997).
Direct introduction of a T-cell derived Tat-associated ki-
nase allowed us to evaluate its role in augmenting Tat
response at the single-cell level.
Tat-associated kinases include the general transcrip-
tion factor TFIIH, Tat-associated kinase TAK/CDK9, and
TTK. The cyclin T facilitates interaction of CDK9 with the
TAR RNA loop structure. Furthermore, cyclin T, which is
encoded on human chromosome 12, when overex-
pressed in murine cells, appears to rescue Tat response
in murine cells, which are otherwise inefficient in Tat
transactivation (reviewed in Cullen, 1998). The CDK9/
cyclin T complex clearly functions as one of the Tat-
associated RNA Pol II CTD kinases. The issue is whether
the same kinase complex is involved throughout the cell
cycle and whether Tat response is regulated in the cell
cycle. Overexpression of CDK9/cyclin T has also been
reported to induce the CMV promoter, indicating a
broader effect of CDK9-mediated induction of transcrip-
tion (Peng et al., 1998). It is possible that CDK9/cyclin T
and TTK simply function at different stages of the cell
cycle. We present data that demonstrate that TTK clearly
functions as one of the Tat-associated factors in G1
phase of the cell cycle, specifically inducing HIV-1 LTR.
In order to gain a better understanding of the TTK-
mediated augmentation of the Tat response, we further
characterized the components of TTK (S. Nekhai et al.,
1999). We argued that TTK might phosphorylate RNA Pol
II CTD directly or indirectly by inducing CAK activity. In
this report in particular, we have addressed the steps
involved in mitogenic stimulation of the host cell that
would specifically induce Tat-mediated transcriptional
activation of the HIV-1 LTR. We argued that Tat-mediated
induction of CAK kinase might maintain RNA polymerase
II in a hyperphosphorylated state and thus sustain the
stimulation of Tat-mediated transcriptional elongation of
the viral promoter (Nekhai et al., 1997). We have shown
that the Tat response and its induction by the Tat-asso-
ciated kinase (TTK) are sensitive to the progression of
cells through G1 phase and in particular to the G1-
specific cyclin-dependent kinase, CDK4. These data rep-
resent the first direct link between cell cycle progression
and Tat response in vivo, although the precise mecha-
nism of G1 CDK-regulated Tat response remains to be
defined.
Particularly intriguing is the effect of a transdominant
Ras mutant on the Tat response. The Ras proto-onco-
gene is an essential component of mitogenic signal
transduction pathways which is required for cells to both
exit the quiescent (G0) state and progress through the
G1/S transition of the cell cycle. Thus, the stimulation of
transactivation by the Tat-associated kinase follows the
cell growth pattern envisioned in viral gene activation.
These results support a model of a general mechanism
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peats (pHAWT), 31 CTD repeats (pHA 31), or only 5 CTD repeats (pHA
5). After 3 h, the culture medium was supplemented with 2.5 mg/ml
252 NEKHAI ET AL.whereby promoter-specific processive transcription in
response to an inducer is accomplished by reconstitut-
ing transcription activators, such as Tat–TTK, to the tran-
scription complex. Furthermore, constitution of such a
transcription complex to induce viral gene expression
appears to be regulated at specific cell cycle stage.
Isolation and molecular characterization of the TTK com-
ponents that appear to reconstitute a CAK activation
complex would enable us to further define the mecha-
nisms by which viral gene activation is regulated by the
cell growth signal transduction pathways.
MATERIALS AND METHODS
Cell synchrony
HS68 (human foreskin fibroblast) cells were cultured
on coverslips (in DMEM supplemented with 10% fetal
bovine serum) until 30–50% confluence. The cultures
were serum starved for 36–48 h to arrest the cells in a
quiescent G0 stage. The serum-starved cells were stim-
ulated with complete medium and thus allowed to enter
G1 phase. To synchronize cells in G2 phase, the serum-
starved culture was induced with complete medium for
90 min and then arrested at the G1/S boundary with 2
mM hydroxyurea for 18 h. Cells complete S phase within
3–4 h after release from hydroxyurea and are in G2
phase between 5 and 8 h, before they reach mitosis.
Preparation of TTK
Partial purification of the TTK by ammonium sulfate
fractionation and DEAE–Sepharose chromatography
was performed as we described earlier (Nekhai et al.,
1997). Briefly, primary human T-lymphocytes induced for
24 h by PHA (Murex Diagnostics, NC) (1 mg/ml) and
phorbol myristate acetate (Sigma, St. Louis, MO) (5 ng/
ml) were lysed in 20 mM HEPES (pH 7.9), 0.1% NP-40, 5
mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 10 mg/ml
protinin. About 15 mg of total protein (combined T-cell
ysates from 10 donors) was fractionated by ammonium
ulfate precipitation (25 to 40% ammonium sulfate cut)
ollowed by chromatography on DEAE–Sepharose. Frac-
ions from the DEAE–Sepharose column containing TTK
ctivity were diluted until the conductivity was equivalent
o 50 mM KCl and loaded on a 50-ml SP-Sepharose
olumn and eluted with a linear gradient of KCl (0.1 to 1
) in buffer A (50 mM HEPES (pH 7.9), 5 mM EDTA, 0.5
M DTT, 0.5 mM PMSF, 10 mg/ml aprotinin in 10% glyc-
erol). A portion of each fraction was incubated with 10 mg
f GST–Tat 72 immobilized on glutathione–agarose
a-aminitin and cells were reinjected with Tat and TTK along with rabbit
IgG marker. Two and one-half hours following the reinjection, cells
were fixed and stained as described under Materials and Methods.FIG. 6. (A) Tat transactivation in vivo requires the CTD repeats of the
RNA Pol II large subunit. HS68 cells injected with the reporter plasmid
pJK2 with or without one of the a-aminitin-resistant large subunit of
RNA Pol II-expressing plasmids containing wild-type CTD repeats
(pHAWT), 31 CTD repeats (pHA 31), or 5 CTD repeats (pHA 5) and the
mutant Pol II construct were allowed to express for 3 h. The culture was
treated with 25 mg/ml a-aminitin for a total of 5 h. Recombinant Tat
rotein was reinjected into cells incubated with a-aminitin. Cells were
fixed and immunostained to evaluate Tat-mediated transactivation.
Total number of cells reinjected in each case varied from 18 to 32. (B)
Induction of transactivation by Tat kinase requires RNA Pol II CTD
repeats. Synchronized HS68 cells were injected with the LTR-LacZ
(pJK2) reporter plasmid with equimolar concentration of a-AMr Pol II
large subunit expression plasmids containing the wild-type CTD re-Total number of reinjected cells for each assay condition ranged from
15 to 25.
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containing 250 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5 mM
DTT, 0.5 mM PMSF, and 10 mg/ml aprotinin followed by
FIG. 7. Inhibition of Tat transactivation by inhibitors of G0/G1 and G1
either control pJK2 plasmid alone or pJK2 plasmid plus a plasmid expres
CDK3, or CDK2, as indicated. Cells were stimulated into mitogenesis
after injection. Staining for b-galactosidase was visualized with FITC-c
s indicated. (B) Quantitation of the data from A. Total number of injecthe kinase buffer (50 mM HEPES (pH 7.9), 10 mM MgCl2,
mM EDTA, and 2.5 mM DTT). CTD kinase activity was
a
Gonitored by incubating 100 ng of GST–CTD in the ki-
ase buffer with 10 mM ATP and 10 mCi of [g-32P]ATP for
0 min at room temperature. Fractions containing Tat-
ssion. (A) Quiescent HS68 human fibroblasts were microinjected with
16, p27 CDK inhibitors, or the dominant negative mutants of Ras, CDK4,
tion of fresh medium plus FCS and fixed for immunofluorescence 3 h
ted antibodies and the injection marker IgGs (stained with Texas red),
lls ranged from 30 to 40 per assay.progre
sing p
by addi
onjugassociated CTD kinase activity were pooled, loaded on
ST–Tat 72 glutathione–agarose column, and eluted
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254 NEKHAI ET AL.with a step gradient of 0.1, 0.5, and 1 M KCl in buffer A.
The TTK activity eluted with 0.5 M KCl was desalted (on
Centricon-10 column) and used for microinjections. Fur-
ther biochemical fractionation of the TTK was over a 1-ml
HiTrap heparin column (Amersham–Pharmacia–Biotech)
and eluted as described for the SP-Sepharose column
above (Nekhai et al., 1997). Active TTK fractions were
further resolved on a 5-ml Econo-Pac CHT-II Cartridge
(ceramic hydroxyapatite; Bio-Rad) and eluted with a lin-
ear gradient of sodium phosphate (pH 6.8) (0.1 to 1 M)
containing 5 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 10
mg/ml aprotinin, and 10% glycerol. Fractions were col-
lected and analyzed for the Tat-associated CTD-kinase
activity as described above.
Plasmids
The reporter plasmid pJK2 (courtesy of Dr. Michael
Emmerman, Fred Hutchinson Cancer Institute, Seattle,
WA) expressed a nuclear localization signal-tagged
b-galactosidase under the control of the HIV-1 LTR
(Kimpton and Emerman, 1992). The reporter plasmids
containing TAR mutants were constructed by PCR ampli-
fication of the HIV-1 LTR sequences containing the indi-
cated mutations in the TAR region followed by subclon-
ing in the plasmid pEQJK, the parent plasmid of pJK2. The
LTR-TAR mutant, LM5, had nucleotides 120 to 157 de-
eted, while LM7 had a deletion of nucleotides 11 to
19, and LM11 had substitutions of the wild-type nucle-
tides UGU (139 to 141) with AGA (Boris-Lawrie et al.,
992; Rounseville and Kumar, 1992). A control reporter
lasmid included LacZ under the control of the b-actin
promoter (courtesy of Dr. J. M. Blanchard, IGM, CNRS,
Montpellier, France). Bacterially expressed HIV-1 Tat pro-
tein (gift from Dr. John Brady, NCI, NIH) was used at 1
mg/ml concentration in 50 mM b-mercaptoethanol.
Plasmids expressing the a-amanitin-resistant large
subunit of the RNA Pol II with (wild-type) 52 CTD repeats
(pHAwt), 31 CTD repeats (pHAD31), or 5 CTD (pHAD5)
repeats were obtained from Dr. J. Corden (Johns Hopkins
University, Baltimore, MD) (Gerber et al., 1995). Ras dom-
inant negative plasmid, RasAsn17 (courtesy of Dr. M. Wei-
ler, Cold Spring Harbor Laboratory), CDK inhibitors p16
nd p21 (from Dr. T. Upton, Dana Farber Cancer Center,
arvard), and the dominant negative CDK2 and CDK4
lasmids (courtesy of Dr. E. Harlow, Harvard Medical
chool) were used to delay G1 progression as described
Peeper et al., 1997).
For the construction of Tet-On system, sequences en-
oding full-length HIV-1 Tat (Tat 86) were PCR amplified
rom a GST–Tat 86 plasmid using a SalI adapter forward
rimer and a reverse primer containing HA-peptide se-
uences. The PCR product was gel purified, cut with SalI
nd HindIII, and cloned in the pTet vector (GIBCO BRL,
D). The Tet-responsive element is located upstream of
he minimal immediate early promoter of CMV, whichrives the expression of Tat in this plasmid (pTet Tat 86).
he plasmid encoding the “reverse” Tet repressor (rTet R)
Gossen et al., 1995; Hillen and Berens, 1994) was ob-
ained from Clontech (Palo Alto, CA). Expression of the
at protein was induced by adding tetracycline (2 mg/ml)
for 30 min.
Microinjection and immunostaining
HS68 cells, normally growing or synchronized in a
particular phase of the cell cycle, were injected with the
reporter plasmid pJK2 or in combination with other ex-
pression vectors. The amount of microinjected proteins
and plasmids was adjusted to about 8–10 molecules of
each component per nuclei, based on the microinjection
volume of 10215 ml and known molecular weights. The
molecular mass of TTK was estimated at about 150,000
kDa by size-exclusion chromatography on Superdex 200
(data not shown). The reporter plasmid DNA, with or
without the TTK, was mixed with rabbit IgGs as marker
just before injection into HS68 cell nuclei. The injected
cells were fixed 2–3 h postinjection with 3.7% formalde-
hyde (in PBS) for 5 min at room temperature. Treatment
conditions are described in figure legends. Fixed cells
were permeabilized (for 20 s) with acetone at 220°C and
immunostained with anti-b-galactosidase mAb, followed
by FITC-conjugated anti-mouse IgG. Rabbit IgG injection
marker was stained with biotinylated anti-rabbit IgG and
secondarily with Texas red-conjugated streptavidin. The
efficiency of Tat response was monitored by counting the
fraction of Texas red-stained cells that also stained with
FITC-conjugated b-galactosidase antibody. It is impor-
tant to note that each batch of cells was injected with the
same mixture of ingredients, such as the reporter plas-
mid DNA, with or without Tat or TTK, and the areas of
injected cells, whether control or experimental, were
marked areas on the same coverslip. Therefore, apart
from the specific contents of the injection, mixtures were
treated identically. In each case the data are represented
as an average of the FITC-positive injected nuclei (usu-
ally between 20 and 40 nuclei were injected for each
assay).
To evaluate the requirement of CTD repeats of the
RNA Pol II large subunit in the Tat response in vivo, the
reporter and the a-amanitin-resistant plasmids (Gerber
et al., 1995) were allowed to express for 18 h prior to
incubation with 2.5 mg/ml a-amanitin followed by rein-
ection with recombinant Tat protein either with or with-
ut TTK fraction.
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